A keystone to the biosimilar approval process, comparative analytical assessments are critical to providing substantive evidence of similarity during non-clinical and clinical studies.
With the right partner and expertise, comprehensive analytical testing can allow you to shorten the clinical development plan and enable a faster path to licensing.
Read our whitepaper to learn how the experts at SGS can help you mitigate the risks associated with biosimilar product development and help you expedite approval.
By downloading this content, I agree that SGS can use my data for the purposes of dealing with my request, in accordance with the SGS Online Privacy Statement. SGS may also contact me with information on webinars, news, and events, and their experts can contact me about testing solutions.